Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.
Research published in the April print edition of the journal Life Science Alliance, shows that antidepressant drugs called FIASMAs, including desipramine, amitriptyline, and nortriptyline, halt the growth or kill four different intracellular bacterial pathogens in tissue cell culture and animal models.
“Antibiotic options for diseases caused by intracellular bacteria are limited because many of these drugs cannot penetrate our cell membranes. In essence, the bacteria are protected,” said Jason Carlyon, Ph.D., leader of the study and professor in the VCU Department of Microbiology and Immunology.
Tetracycline antibiotics are most commonly prescribed to treat intracellular bacterial infections because they can cross cell membranes to reach the microbes. However, tetracyclines can cause allergic reactions in some patients and physicians advise against their use by pregnant women and children due to undesirable side effects. Additionally, antibiotic resistance in some intracellular bacteria has been reported.
“It would be highly beneficial to have a class of drugs to treat such diseases in patients for whom tetracyclines are contraindicated,” Carlyon said. “These drugs could provide an alternative to antibiotics or even be used in conjunction with them as an augmentation approach to treat infections that typically require prolonged courses of antibiotic therapy, such as those caused by Chlamydia pneumoniae and Coxiella burnetti.”
The team of researchers from VCU, Indiana University Medical Center, University of Nebraska Medical Center, University of Arkansas for Medical Sciences, and the University of South Florida, including Carlyon and lead author Chelsea Cockburn, an M.D.-Ph.D. candidate, are the first to investigate the mechanisms by which FIASMAs target multiple intracellular bacteria in detail.
The scientists tested FIASMA susceptibility for four bacterial species that cause human granulocytic anaplasmosis, a tick-borne disease that attacks white blood cells called neutrophils and can be fatal to immune compromised individuals; Q fever, a debilitating pneumonic disease; and two chlamydia infections.
FIASMAs ultimately disrupt how cholesterol, a key nutrient utilized by many intracellular pathogens, traffics inside cells to alter bacterial access to the lipid. The researchers first proved FIASMA treatment efficacy by halting anaplasmosis in both tissue culture and mice. Next, they extended their observations to demonstrate that FIASMA treatment killed the Q fever agent,Coxiella burnetii, and partially inhibited chlamydial infections in cell culture.
“Since FIASMAs influence cholesterol trafficking in the cell and cholesterol plays a role in so many facets of our biology, they have been used to treat a wide variety of conditions and diseases,” Carlyon said.
He added that the effect of FIASMAs on intracellular cholesterol ultimately bypasses the need to directly target the bacteria.
“What is so exciting about this study is that the class of drugs we evaluated targets an enzyme in our cells regulating cholesterol, not the bacteria,” Carlyon said. “I do not envision the pathogens being able to develop resistance to this treatment because it is targeting a host pathway that they very much need to grow and survive inside of the body.”
The Latest on: Alternative to antibiotics
via Google News
The Latest on: Alternative to antibiotics
- Swedish scientists have developed a hydrogel to prevent and treat wound infectionson January 9, 2020 at 4:02 pm
An alternative to antibiotics The authors of the study, which has been published in Science Translational Medicine, insist on the need to find alternatives to treatment with antibiotics, which are too ...
- Antibacterial photodynamic inactivation of antibiotic-resistant bacteria and biofilms with nanomolar photosensitizer concentrationson January 9, 2020 at 1:15 am
Find more information on the Altmetric Attention Score and how the score is calculated. Gram-negative bacteria and bacteria in biofilms are very difficult to eradicate and are at the origin of the ...
- Gladskin Launches in USA - Micreos Scaling up to Deliver Award Winning Technology Worldwideon January 9, 2020 at 12:32 am
Dutch biotechnology company Micreos is launching its Gladskin brand in the United States. With this step, the company reinforces its commitment to make its technology, set to replace antibiotics, ...
- Millions of children receive unnecessary medical care, including prescription drugs, cervical-cancer screenings and antibioticson January 8, 2020 at 8:38 am
Health-care professionals advise parents to ask doctors they are jumping to the most extreme treatment and to enquire about the risks of any suggested care.
- Cargill sees 61% increase in Q2 profits after shifting business to offset disruptionson January 7, 2020 at 7:15 pm
The Minnetonka-based agribusiness was able to use size to its advantage. While Cargill Inc. continues to grapple with ongoing trade uncertainties that are hitting its North American growers ...
- Say hello to Impossible Pork, the next generation of fake meaton January 7, 2020 at 1:31 pm
Impossible’s founder Patrick Brown says the company’s mission is to "eliminate the need for animals in the food chain and make the global food system sustainable," and giving meat eaters an ...
- As drug companies go bust, the discovery of new antibiotics is stuntedon January 6, 2020 at 2:24 am
Antibiotic resistance means a growing number of bacteria no longer respond to once effective drugs, turning “harmless” infections into deadly diseases. The World Health Organization calls it “one of ...
- What to do when a generic antibiotic does not workon January 4, 2020 at 9:00 pm
I recently had bronchitis and took the generic antibiotic doxycycline. It had no effect ... That way, you can be assured there are no contaminants and that the product contains the right amount of ...
- New agents to fight multidrug-resistant germson January 3, 2020 at 5:19 am
Resistance to antibiotics is on the rise worldwide. Fraunhofer scientists have joined forces with partners in the Phage4Cure project to explore alternatives to antibiotics. One objective is to ...
- Antibiotics maker Melinta files for bankruptcy, raising red flags about financial strength of manufacturers of the drugon January 2, 2020 at 1:58 pm
It joins antibiotic startups Achaogen and Aradigm that also sought bankruptcy protection last year. The bankruptcy move was not a surprise. Melinta warned in a regulatory filing in November that it ...
via Bing News